Jazz Pharmaceuticals JAZZ Defitelio — Revenue
Discontinued — last reported Q2 '18
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed August 7, 2018, on SEC EDGAR. View the filing →
Questions, answered.
- What does defitelio — revenue mean?
- The net sales revenue generated from the sale of the drug Defitelio after accounting for all commercial adjustments.
- How do you interpret defitelio — revenue?
- An increase indicates growing market demand, successful clinical adoption, or expanded patient access for the treatment. A decrease may signal increased competition, loss of market exclusivity, or changes in clinical treatment guidelines.
- How does defitelio — revenue compare across companies?
- Comparable to product-specific net revenue lines reported by other specialty biopharmaceutical companies, often categorized under oncology or rare disease therapeutic segments.